MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from disposal of
investments in equity...
$1,020,873
Advances from directors
$34,187
Dividend income
$4,192
Net cash generated
from/(used in) investing...
$994,646
Net cash generated
from financing...
$34,187
Foreign currency
translation adjustment
$28,535
Canceled cashflow
$30,419
Net change in cash
and cash...
-$180,097
Canceled cashflow
$1,057,368
Inventories
-$208,175
Trade and other
receivables
-$206,475
Change in fixed
deposits placed with...
$15,872
Acquisition of investments
in equity...
$9,064
Purchase of plant and
equipment
$5,483
Net cash used in
operating activities
-$1,237,465
Canceled cashflow
$414,650
Allowances for expected
credit losses
$175,818
Depreciation of property,
plant and equipment
$29,001
Amortization of right-of-use
asset
$14,354
Trade and other
payables
-$1,114,895
Operating loss before
working capital changes
-$521,557
Canceled cashflow
$219,173
Operating lease
liabilities
-$13,410
Tax
(liabilities)/recoverable
$2,169
Advance payment from
customer
-$84
Net loss
$708,991
Gain on disposal of
investments in equity...
$27,547
Dividend income
$4,192
Back
Back
Cash Flow
source: myfinsight.com
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)